{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T10:43:38Z","timestamp":1786704218623,"version":"build-2736575974"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T00:00:00Z","timestamp":1648166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Toripalimab (Junshi Bioscience Co., Ltd) is a new immune checkpoint inhibitor (ICI) that targets programmed cell death protein 1 (PD-1) in various cancers, including metastatic melanoma. No neurological immune-related adverse events (n-irAEs) of toripalimab have been reported, except for neuromuscular involvement. We report a case of a 63-year-old woman who presented with severe vertigo, vomiting, nystagmus, cerebellar ataxia, and cognitive impairment after toripalimab treatment for metastatic melanoma. Compared with the concomitant cognitive dysfunction and a pathological reflex involving the cerebral cortex, the signs and symptoms of cerebellar involvement were much more prominent. Anti-glutamic acid decarboxylase 65 (anti-GAD65) antibody was positive in both serum and cerebrospinal fluid (CSF). After intravenous immunoglobulin (IVIG) and methylprednisolone (IVMP) administration, the symptoms of vertigo and vomiting resolved, with cognitive impairment and cerebellar ataxia remaining. This is the first report of autoimmune encephalitis (AIE) as an n-irAE of toripalimab.<\/jats:p>","DOI":"10.3389\/fimmu.2022.850540","type":"journal-article","created":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T12:48:20Z","timestamp":1648558100000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Anti-GAD65 Antibody-Associated Autoimmune Encephalitis With Predominant Cerebellar Involvement Following Toripalimab Treatment: A Case Report of a Novel irAE of Toripalimab"],"prefix":"10.3389","volume":"13","author":[{"given":"Huanyu","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxi","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menghan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianhua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-018-0810-1","article-title":"Neurological Adverse Events Associated With Immune Checkpoint Inhibitors: Diagnosis and Management","volume":"18","author":"Astaras","year":"2018","journal-title":"Curr Neurol Neurosci"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.714460","article-title":"Case Report: The Neuromusclar Triad of Immune Checkpoint Inhibitors: A Case Report of Myositis, Myocarditis, and Myasthenia Gravis Overlap Following Toripalimab Treatment","volume":"8","author":"Luo","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-020-0359-x","article-title":"GAD Antibodies in Neurological Disorders - Insights and Challenges","volume":"16","author":"Graus","year":"2020","journal-title":"Nat Rev Neurol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/2548528","article-title":"Nivolumab-Induced Autoimmune Encephalitis in Two Patients With Lung Adenocarcinoma","volume":"2018","author":"Shah","year":"2018","journal-title":"Case Rep Neurol Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-021-05312-0","article-title":"GAD65 Autoimmunity After Treatment With Nivolumab: A Multifocal Presentation","volume":"42","author":"Maniscalco","year":"2021","journal-title":"Neurol Sci"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-019-09666-6","article-title":"Immune Checkpoint Inhibitor Induced Anti-Glutamic Acid Decarboxylase 65 (Anti-GAD 65) Limbic Encephalitis Responsive to Intravenous Immunoglobulin and Plasma Exchange","volume":"267","author":"Chung","year":"2020","journal-title":"J Neurol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000011795","article-title":"Neurologic Adverse Events of Immune Checkpoint Inhibitors A Systematic Review","volume":"96","author":"Marini","year":"2021","journal-title":"Neurology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000012122","article-title":"Autoimmune Encephalitis Related to Cancer Treatment With Immune Checkpoint Inhibitors A Systematic Review","volume":"97","author":"Nersesjan","year":"2021","journal-title":"Neurology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002890","article-title":"Consensus Disease Definitions for Neurologic Immune-Related Adverse Events of Immune Checkpoint Inhibitors","volume":"9","author":"Guidon","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0617-x","article-title":"Neurologic Toxicity Associated With Immune Checkpoint Inhibitors: A Pharmacovigilance Study","volume":"7","author":"Johnson","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.8895-17","article-title":"Acute Cerebellar Ataxia Induced by Nivolumab","volume":"56","author":"Kawamura","year":"2017","journal-title":"Internal Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocpiqo.2017.12.001","article-title":"Association of Immune-Mediated Cerebellitis With Immune Checkpoint Inhibitor Therapy","volume":"2","author":"Zurko","year":"2018","journal-title":"Mayo Clinic Proc Innovations Qual Outcomes"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2019-231520","article-title":"Acute Cerebellar Ataxia Due to Epstein-Barr Virus Under Administration of an Immune Checkpoint Inhibitor","volume":"12","author":"Saikawa","year":"2019","journal-title":"BMJ Case Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2020-235607","article-title":"Case of Anti-Zic4 Antibody-Mediated Cerebellar Toxicity Induced by Dual Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma","volume":"13","author":"Iyer","year":"2020","journal-title":"BMJ Case Rep"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s11481-021-10026-3","article-title":"Immune-Related Cerebellar Ataxia: A Rare Adverse Effect of Checkpoint Inhibitor Therapy","author":"Sebbag","year":"2021","journal-title":"J Neuroimmune Pharmacol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000000604","article-title":"Increased Frequency of Anti-Ma2 Encephalitis Associated With Immune Checkpoint Inhibitors","volume":"6","author":"Vogrig","year":"2019","journal-title":"Neurology-Neuroimmunol Neuroinflamm"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyz087","article-title":"Nivolumab-Induced Autoimmune Encephalitis in an Anti-Neuronal Autoantibody-Positive Patient","volume":"49","author":"Shibaki","year":"2019","journal-title":"Jpn J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0487","article-title":"Neurologic Serious Adverse Events Associated With Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis","volume":"22","author":"Larkin","year":"2017","journal-title":"Oncologist"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0727-5","article-title":"Unchecked Immunity: A Unique Case of Sequential Immune-Related Adverse Events With Pembrolizumab","volume":"7","author":"Shah","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2016.12.016","article-title":"Autoimmune Limbic Encephalitis With Anti-Contactin-Associated Protein-Like 2 Antibody Secondary to Pembrolizumab Therapy","volume":"305","author":"Brown","year":"2017","journal-title":"J Neuroimmunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000000439","article-title":"Natalizumab may Control Immune Checkpoint Inhibitor-Induced Limbic Encephalitis","volume":"5","author":"Hottinger","year":"2018","journal-title":"Neurology-Neuroimmunol Neuroinflamm"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2020.577259","article-title":"Glial Fibrillary Acidic Protein (GFAP) Associated Autoimmune Meningoencephalitis in a Patient Receiving Nivolumab","volume":"344","author":"Kapadia","year":"2020","journal-title":"J Neuroimmunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.71.1.100","article-title":"Antibodies Against Glutamic Acid Decarboxylase: Prevalence in Neurological Diseases","volume":"71","author":"Meinck","year":"2001","journal-title":"J Neurol Neurosur Ps"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2015.03.009","article-title":"GAD65 Epitope Mapping and Search for Novel Autoantibodies in GAD-Associated Neurological Disorders","volume":"281","author":"Fouka","year":"2015","journal-title":"J Neuroimmunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/mus.25565","article-title":"GAD65 Neurological Autoimmunity","volume":"56","author":"McKeon","year":"2017","journal-title":"Muscle Nerve"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000000696","article-title":"Neurologic Syndromes Related to Anti-GAD65 Clinical and Serologic Response to Treatment","volume":"7","author":"Munoz-Lopetegi","year":"2020","journal-title":"Neurology-Neuroimmunol Neuroinflamm"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra023009","article-title":"Paraneoplastic Syndromes Involving the Nervous System","volume":"349","author":"Darnell","year":"2003","journal-title":"New Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0194-4","article-title":"Paraneoplastic Neurological Syndromes in the Era of Immune-Checkpoint Inhibitors","volume":"16","author":"Graus","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/ana.10518","article-title":"Anti-Neuronal Nuclear Autoantibody Type 2: Paraneoplastic Accompaniments","volume":"53","author":"Pittock","year":"2003","journal-title":"Ann Neurol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/0166-2236(89)90109-4","article-title":"Autoimmunity To The Voltage-Gated Calcium-Channel Underlies The Lambert-Eaton Myasthenic Syndrome, A Para-Neoplastic Disorder","volume":"12","author":"Vincent","year":"1989","journal-title":"Trends Neurosci"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.42.10.1931","article-title":"Paraneoplastic Cerebellar Degeneration. I. A Clinical Analysis of 55 Anti-Yo Antibody-Positive Patients","volume":"42","author":"Peterson","year":"1992","journal-title":"Neurology"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/ana.23550","article-title":"Identification of Delta\/Notch-Like Epidermal Growth Factor-Related Receptor as the Tr Antigen in Paraneoplastic Cerebellar Degeneration","volume":"71","author":"de Graaff","year":"2012","journal-title":"Ann Neurol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000001721","article-title":"Paraneoplastic Neurologic Disorders in Small Cell Lung Carcinoma: A Prospective Study","volume":"85","author":"Gozzard","year":"2015","journal-title":"Neurology"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000010632","article-title":"Neurologic Autoimmunity and Immune Checkpoint Inhibitors: Autoantibody Profiles and Outcomes","volume":"95","author":"Sechi","year":"2020","journal-title":"Neurology"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2013.08.026","article-title":"Paraneoplastic Cerebellar Degeneration With Anti-Yo Antibodies Associated With Metastatic Uveal Melanoma","volume":"335","author":"Valpione","year":"2013","journal-title":"J Neurol Sci"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.77.6385","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.0249","article-title":"Encephalitis Induced by Immune Checkpoint Inhibitors A Systematic Review","volume":"78","author":"Velasco","year":"2021","journal-title":"JAMA Neurol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.850540\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T12:48:23Z","timestamp":1648558103000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.850540\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,25]]},"references-count":37,"alternative-id":["10.3389\/fimmu.2022.850540"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.850540","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,25]]},"article-number":"850540"}}